[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Are Wall Street Analysts Bullish on Pfizer Stock?

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $152.3 billion, the company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas.

Shares of this pharmaceutical giant have underperformed the broader market over the past year. PFE has gained 16.9% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 29.8%. However, in 2026, PFE stock is up 7.6%, surpassing SPX’s 4.8% rise on a YTD basis. 

Fundamentals

See More
  • Market Capitalization, $K 152,335,136
  • Shares Outstanding, K 5,686,268
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,118 M
  • EBITDA $ 25,710 M
  • 60-Month Beta 0.43
  • Price/Sales 2.45
  • Price/Cash Flow 6.14
  • Price/Book 1.77

Options Overview Details

View History
  • Implied Volatility 27.56% (-0.33%)
  • Historical Volatility 22.13%
  • IV Percentile 76%
  • IV Rank 58.54%
  • IV High 34.15% on 10/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 2) 0.52 (1.96%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 167,435
  • Volume Avg (30-Day) 112,215
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 2,469,325
  • Open Int (30-Day) 2,429,881
  • Expected Range 25.96 to 27.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.74
  • Number of Estimates 7
  • High Estimate $0.90
  • Low Estimate $0.66
  • Prior Year $0.92
  • Growth Rate Est. (year over year) -19.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.32 +0.61%
on 04/28/26
28.75 -7.88%
on 04/02/26
-0.56 (-2.07%)
since 03/27/26
3-Month
25.26 +4.83%
on 02/03/26
28.75 -7.88%
on 04/02/26
+0.62 (+2.40%)
since 01/28/26
52-Week
21.97 +20.53%
on 05/14/25
28.75 -7.88%
on 04/02/26
+3.43 (+14.88%)
since 04/28/25

Most Recent Stories

More News
Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the...

PFE : 26.48 (-1.16%)
Are Wall Street Analysts Bullish on Pfizer Stock?

Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

$SPX : 7,138.80 (-0.49%)
PJP : 103.98 (+0.16%)
PFE : 26.48 (-1.16%)
Unusual Put Activity Is Flagging a Smart Trade Setup in This New Quantum Computing Stock

Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s...

INFQ : 12.62 (-5.11%)
PFE : 26.48 (-1.16%)
Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

MRK : 110.03 (-0.18%)
PFE : 26.48 (-1.16%)
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

Expands Options for Cash-Paying Patients to Access the Nation’s #1 Prescribed Oral Blood Thinner

PFE : 26.48 (-1.16%)
BMY : 58.26 (+0.83%)
Pfizer Declares Second-Quarter 2026 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

PFE : 26.48 (-1.16%)
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

New evidence for established standard-of-care therapies, with updates for LORBRENA ® in ALK-positive metastatic non ‑ small cell lung cancer...

PFE : 26.48 (-1.16%)
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

TOKYO and NEW YORK , April 20, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug...

PFE : 26.48 (-1.16%)
2 Value Stocks to Research Further and 1 Facing Headwinds

2 Value Stocks to Research Further and 1 Facing Headwinds

OCSL : 12.63 (+2.43%)
HPE : 27.95 (-2.34%)
PFE : 26.48 (-1.16%)
Earnings Preview: What to Expect From Pfizer’s Report

Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range.

XLV : 143.84 (+0.26%)
$SPX : 7,138.80 (-0.49%)
PFE : 26.48 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 28.53
2nd Resistance Point 28.05
1st Resistance Point 27.27
Last Price 26.48
1st Support Level 26.01
2nd Support Level 25.53
3rd Support Level 24.75

See More

52-Week High 28.75
Last Price 26.48
Fibonacci 61.8% 26.16
Fibonacci 50% 25.36
Fibonacci 38.2% 24.56
52-Week Low 21.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.